Neuland Laboratories (524558) Q4 12/13 earnings summary

Executive summary

• FY13 delivered modest revenue growth but sharply higher EBITDA and PAT, supported by cost and process improvements, lower interest expense, and a strategic reorganization.

• Focus shifted toward API manufacturing, intermediates, niche high-margin products, and contract manufacturing; research and peptide activities were transferred to affiliated entities.

Financial highlights

• Standalone net revenue rose 3.10% YoY to ₹4,639.04 million; EBITDA increased 27.09% to ₹614.45 million.

• Standalone PAT climbed 571.11% to ₹136.37 million from ₹20.32 million; FY13 included discontinued-operations losses of ₹22.97 million after tax.

• Consolidated revenue was ₹4,639.56 million and PAT was ₹138.63 million; consolidated EPS was ₹18.13 basic and ₹18.12 diluted.

• Operating costs increased 0.22% to ₹4,024.59 million; finance costs declined to ₹313.30 million from ₹332.74 million.

Outlook and guidance

• Management expected growth momentum to continue in FY14 and beyond, driven by niche high-margin products, portfolio expansion, process efficiency, and contract manufacturing.

• Nine existing products were expected to scale up commercially in FY14; a pipeline of 19 molecules targeted launches during 2013–16.

• The Mitsubishi Chemical API Corporation arrangement was expected to begin operations in Q4 FY14, with dedicated capacity assigned to manufacturing requirements.